Cardiology Pharmaceuticals

Verve Vaults Forward From Topline Results

Completing its pharma comeback story, Verve Therapeutics announced successful results from the Heart-2 Phase 1b Clinical Trial of its in-vivo base editing drug, VERVE-102, that targets the PCSK9 gene for reducing LDL-C.

  • PCSK9 is a molecule that breaks down LDL receptors, so drugs that inhibit it force the body’s LDL receptors to work harder, which reduces LDL-C more efficiently.
  • Currently there are two FDA approved PCSK9 inhibitors, Amgen’s Repatha (evolocumab) and Regeneron’s Praluent (alirocumab), both of which are injected every three months.
  • VERVE-102 is different since it edits and inactivates the gene responsible for PCSK9 production, meaning a single injection could permanently lower a patient’s LDL-C levels.

VERVE-102’s topline results come from a small group of 14 patients across three different dose cohorts (weight-based cohorts of 0.3, 0.45, and 0.6mg/kg) with at least 28 days of follow-up for each participant.

  • After 28 days, researchers found that a single infusion of VERVE-102 led to an average LDL-C reduction of 53% with a maximum reduction of 69% in the 0.6mg/kg dose cohort.
  • The 0.3mg/kg cohort saw a 21% LDL-C reduction and a 46% PCSK9 reduction, while the 0.45mg/kg cohort saw a 41% LDL-C and 53% PCSK9 reduction.

Not only was VERVE-102’s gene editing effective, it was also safe, with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level.

  • This stems from VERVE-102’s proprietary GalNAc-LNP delivery technology, which allows the drug to access liver cells and demonstrates a potentially best-in-class safety profile.

These successful results mark a comeback for Verve considering the adverse events that led to the discontinuation of its earlier LDL-C drug, VERVE-101.

  • Now with the topline success of VERVE-102, Verve will move on to Phase 2 of Heart-2 with a fourth dose cohort of 0.7mg/kg while it awaits Eli Lilly’s PCSK9 opt-in decision.
  • Under a PCSK9 collaboration agreement with Verve, Lilly can opt-in to share worldwide development expenses (33% from Lilly) and profits in the U.S. on a 50/50 basis.

The Takeaway

Although we’re still very early in the gene editing space, and even earlier in single-shot CVD treatments, a single-dose injectable for LDL-C could have a lot of appeal if the price is right, gene editing catches on, and if future trials yield similarly supportive results

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

This content is exclusive to subscribers

Log in or join by entering your email below.

Completely free. Every Monday and Thursday.

CW Phone Square

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!